What Is Grace Therapeutics, Inc. (GRCE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Grace Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $3.46. While the stock appears modestly undervalued at $2.43 (implied upside of +42.4%), our analysis suggests a thinner margin of safety across 5 of 7 bullish models. Notably, ML-RIV sees the most upside at +92.9% (fair value: $4.69), while Bayesian DCF is the most conservative at -41.1% ($1.43). The spread between these extremes — +134.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About GRCE?
7 of 13 models are currently active for GRCE. Of these, 5 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates GRCE's intrinsic value at $1.43, implying -41.1% downside from the current price. See which stocks rank higher →
How Does GRCE Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, GRCE ranks #232 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Grace Therapeutics, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is GRCE a Value Trap?
CirclFi's Value Trap algorithm assigns GRCE a score of 52/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Grace Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Grace Therapeutics, Inc. is rated at 4.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +134.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every GRCE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across GRCE's 7 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad